DOI:
10.1055/s-00000019
Fortschritte der Neurologie · Psychiatrie
LinksClose Window
References
Cohen JA, Coles AJ, Arnold DL et al.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Lancet 2012;
380: 1819-1828
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.